← Leaderboards
Steven Hsu
Johns Hopkins University
$2,143,227
Attributed
$2,143,227
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $709.5K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,143,227 · 2
By mechanism
R01$1,257,627 · 1
K23$885,600 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Nazareno Paolocci$4,852,341
- William B Mathews$1,405,180
- Kenneth D. Karlin$16,339,237
- Andrea C Gielen$24,074,508
- Bryan Kevin Ward$991,487
Others in their field
Other Emerging Leaders on “Primary Pulmonary Hypertension”
- Mara Becker · Duke University$6,798,777
- Peter J Leary · University Of Washington$6,420,826
- Zhiyu Dai · University Of Arizona$5,306,571
- Christoph Hornik · Duke University$3,797,547
- Roham Zamanian · Stanford University$2,837,578
- Erica J Carrier · Vanderbilt University Medical Center$2,201,750
Research focus
Primary Pulmonary HypertensionRestMyosin-Binding Protein CPressurePulmonary HypertensionResponseHemodynamicsMyocardiumNational Heart, Lung, And Blood InstitutePhysiologic Intraventricular PressureProspectiveProteinsCardiac MyocytesResearch PersonnelFailureFunctional DisorderIncubatedMuscle CellsBiopsyDepressed MoodPharmaceutical PreparationsPhosphorylationCalciumRight Ventricular Dysfunction
Grant awards (7)
Myocyte Mechanics of Right Ventricular Contractile Failure in Pulmonary Hypertension due to Heart Failure with Reduced Ejection Fraction$709,506
R01 · FY2025 · HL · contact PI
Myocyte Mechanics of Right Ventricular Contractile Failure in Pulmonary Hypertension due to Heart Failure with Reduced Ejection Fraction$548,121
R01 · FY2024 · HL · contact PI
Mechanisms and treatment of right ventricular sarcomere dysfunction in scleroderma-associated pulmonary arterial hypertension$177,120
K23 · FY2023 · HL · contact PI
Mechanisms and treatment of right ventricular sarcomere dysfunction in scleroderma-associated pulmonary arterial hypertension$177,120
K23 · FY2022 · HL · contact PI
Mechanisms and treatment of right ventricular sarcomere dysfunction in scleroderma-associated pulmonary arterial hypertension$177,120
K23 · FY2021 · HL · contact PI
Mechanisms and treatment of right ventricular sarcomere dysfunction in scleroderma-associated pulmonary arterial hypertension$177,120
K23 · FY2020 · HL · contact PI
Mechanisms and treatment of right ventricular sarcomere dysfunction in scleroderma-associated pulmonary arterial hypertension$177,120
K23 · FY2019 · HL · contact PI